Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

72.07 +2.69 (+3.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 Next >
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Via The Motley Fool
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts
Via Benzinga
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
The company provides sequencing tools to help diagnose children with rare diseases. 
Via Investor's Business Daily
Expert Ratings For GeneDx Hldgs
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue. 
Via Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
The Markets Are Ignoring Risk, But That Does Not Mean You Should...
It is Fall clean-up time. Sell lagging and sagging companies. 
Via Talk Markets
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Latest Analyst Ratings For GeneDx Hldgs
Via Benzinga
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga
7 Small-Cap Stocks With Massive Potential Returns
Explore these small-cap stocks with high potential in health care, REITs, entertainment, hardware, finance, and distribution industries. 
Via InvestorPlace
Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Over $4M Bet On ProFrac Holding? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Gold Down Over 2%; 3M Profit Beats Expectations
Via Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Eli Lilly Increases FY24 Outlook, Joins Brinker International, Zebra Technologies, 3M And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today! 
Via InvestorPlace
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q1 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
GeneDx Stock Climbs After Better-Than-Expected Q1 Results, Raises FY24 Guidance
GeneDx reports quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents by 50.75%. The company reported quarterly sales of $62.422 million which beat the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.